Baillie Gifford & Co’s Teva Pharmaceuticals TEVA Stock Holding History

Baillie Gifford & Co’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-69,350	Closed	-$4.32M	–	211
2015 Q1	$4.32M	Hold	69,350	–	–	0.01%	170
2014 Q4	$3.99M	Hold	69,350	–	–	0.01%	171
2014 Q3	$3.73M	Hold	69,350	–	–	0.01%	176
2014 Q2	$3.63M	Hold	69,350	–	–	0.01%	180
2014 Q1	$3.66M	Hold	69,350	–	–	0.01%	180
2013 Q4	$2.78M	Hold	69,350	–	–	0.01%	171
2013 Q3	$2.62M	Hold	69,350	–	–	0.01%	160
2013 Q2	$2.72M	Buy	+69,350	New	+$2.7M	0.01%	137

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Baillie Gifford & Co's TEVA Position: Q2 2015 in Review

Baillie Gifford & Co sold out of Teva Pharmaceuticals (TEVA) in Q2 2015, closing a stake of 69,350 shares — an estimated $4.32M sold.

Baillie Gifford & Co first reported a position in TEVA in Q2 2013 and held it in 8 quarters. The position peaked at $4.32M in Q1 2015. 818 funds tracked by Wall St. Rank hold TEVA as of Q2 2015.

Baillie Gifford & Co reported no remaining Teva Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
Baillie Gifford & Co sold 69,350 Teva Pharmaceuticals shares in Q2 2015, an estimated $4.32M.
Baillie Gifford & Co first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 8 quarters.
Baillie Gifford & Co's Teva Pharmaceuticals position peaked at $4.32M in Q1 2015.
818 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2015.

Based on Baillie Gifford & Co's 13F filing for Q2 2015, filed 28 Jul 2015.